Based on the molecular typing of breast cancer, there are now five types. The most commonly used one now is epidermal growth factor receptor 2, called HER-2 gene. If this gene is positive, it is called HER-2 positive type. There are also negative or positive estrogen receptors and progesterone receptors. If the patient is positive for both estrogen receptor and progesterone receptor and has a low proliferation index Ki-67 or is HER-2 negative, the patient is classified as Luminal A. If the patient has a low proliferation index Ki-67 or is HER-2 negative, the patient is classified as Luminal A. Patients with positive or high proliferation index Ki-67, negative or low expression of progesterone receptor PR and positive estrogen receptor ER are classified as Luminal B. Patients who are HER-2 positive, ER positive or negative, and PR positive or negative are classified as a special type. For patients who are negative for all molecular markers, it is called triple negative breast cancer. Therefore, the molecular staging of breast cancer is determined based on these molecular markers. Patients with different types of breast cancer need to receive different treatments. After individualized treatment of breast cancer, better clinical outcomes can be obtained.